Filtered By:
Source: European Heart Journal
Condition: Heart Failure

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 60 results found since Jan 2013.

Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial
Conclusions Sizeable reductions in BP, with potential for substantial CVD reduction, can be safely achieved using combinations of BP drugs in the elderly with normal high and Stage 1 hypertension. Clinical trial registration NCT01259297.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Teo, K. K., Pfeffer, M., Mancia, G., O'Donnell, M., Dagenais, G., Diaz, R., Dans, A., Liu, L., Bosch, J., Joseph, P., Copland, I., Jung, H., Pogue, J., Yusuf, S., on behalf of the Aliskiren Prevention of Later Life Outcomes trial Investigators Tags: Hypertension Source Type: research

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Conclusions Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Sorbets, E., Labreuche, J., Simon, T., Delorme, L., Danchin, N., Amarenco, P., Goto, S., Meune, C., Eagle, K. A., Bhatt, D. L., Steg, P. G. Tags: Coronary artery disease Source Type: research

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial
Conclusion In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
Source: European Heart Journal - July 15, 2014 Category: Cardiology Authors: Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D., Deedwania, P., Kostis, J. B., Messerli, F. H., Treating to New Targets Steering Committee and Investigators Tags: Heart failure/cardiomyopathy Source Type: research

Perioperative risk of major non-cardiac surgery in patients with severe aortic stenosis: a reappraisal in contemporary practice
Conclusion Severe aortic stenosis is associated with increased risk of MACE. In contemporary practice, perioperative mortality of patients with SAS is lower than previously reported and the difference from controls did not reach statistical significance. Emergency surgery is the strongest predictor of post-operative death. These results have implications for perioperative risk assessment and management strategies in patients with SAS.
Source: European Heart Journal - September 14, 2014 Category: Cardiology Authors: Tashiro, T., Pislaru, S. V., Blustin, J. M., Nkomo, V. T., Abel, M. D., Scott, C. G., Pellikka, P. A. Tags: Valvular heart disease Source Type: research

Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
This study is registered at clinicaltrials.gov-NCT00417222.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Sakata, Y., Shiba, N., Takahashi, J., Miyata, S., Nochioka, K., Miura, M., Takada, T., Saga, C., Shinozaki, T., Sugi, M., Nakagawa, M., Sekiguchi, N., Komaru, T., Kato, A., Fukuchi, M., Nozaki, E., Hiramoto, T., Inoue, K., Goto, T., Ohe, M., Tamaki, K., I Tags: Heart failure/cardiomyopathy Source Type: research

Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence
Conclusion Regardless of recent advances in PAD treatment, current outcomes remain poor especially in CLI. Despite overwhelming evidence for reduction of limb loss by revascularization, CLI patients still received significantly less angiographies and revascularizations.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Reinecke, H., Unrath, M., Freisinger, E., Bunzemeier, H., Meyborg, M., Luders, F., Gebauer, K., Roeder, N., Berger, K., Malyar, N. M. Tags: Peripheral artery disease Source Type: research

Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)
Conclusion Rheumatic heart disease patients were young, predominantly female, and had high prevalence of major cardiovascular complications. There is suboptimal utilization of secondary antibiotic prophylaxis, oral anti-coagulation, and contraception, and variations in the use of percutaneous and surgical interventions by country income level.
Source: European Heart Journal - May 7, 2015 Category: Cardiology Authors: Zuhlke, L., Engel, M. E., Karthikeyan, G., Rangarajan, S., Mackie, P., Cupido, B., Mauff, K., Islam, S., Joachim, A., Daniels, R., Francis, V., Ogendo, S., Gitura, B., Mondo, C., Okello, E., Lwabi, P., Al-Kebsi, M. M., Hugo-Hamman, C., Sheta, S. S., Haile Tags: Valvular heart disease Source Type: research

Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)
Conclusion Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure. Study registration number NCT00644410 (ClinicalTrials.gov).
Source: European Heart Journal - July 14, 2015 Category: Cardiology Authors: Mathiasen, A. B., Qayyum, A. A., Jorgensen, E., Helqvist, S., Fischer-Nielsen, A., Kofoed, K. F., Haack-Sorensen, M., Ekblond, A., Kastrup, J. Tags: Interventional cardiology Source Type: research

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - August 7, 2015 Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research

Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
Conclusions The blinded placebo-controlled STOP-HF trial demonstrated the safety of a single endocardial administration of pSDF-1 but failed to demonstrate its primary endpoint of improved composite score at 4 months after treatment. Through a pre-specified analysis the STOP-HF trial demonstrates the potential for attenuating LV remodelling and improving EF in high-risk ischaemic cardiomyopathy. The safety profile supports repeat dosing with pSDF-1 and the degree of left ventricular remodelling suggests the potential for improved outcomes in larger future trials.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Chung, E. S., Miller, L., Patel, A. N., Anderson, R. D., Mendelsohn, F. O., Traverse, J., Silver, K. H., Shin, J., Ewald, G., Farr, M. J., Anwaruddin, S., Plat, F., Fisher, S. J., AuWerter, A. T., Pastore, J. M., Aras, R., Penn, M. S. Tags: Heart failure/cardiomyopathy Source Type: research

Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts
Conclusion In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice.
Source: European Heart Journal - December 21, 2015 Category: Cardiology Authors: Olson, K. A., Beatty, A. L., Heidecker, B., Regan, M. C., Brody, E. N., Foreman, T., Kato, S., Mehler, R. E., Singer, B. S., Hveem, K., Dalen, H., Sterling, D. G., Lawn, R. M., Schiller, N. B., Williams, S. A., Whooley, M. A., Ganz, P. Tags: Pathophysiology Source Type: research

Heart failure: when form fails to follow function
Cardiac performance is normally determined by architectural, cellular, and molecular structures that determine the heart's form, and by physiological and biochemical mechanisms that regulate the function of these structures. Impaired adaptation of form to function in failing hearts contributes to two syndromes initially called systolic heart failure (SHF) and diastolic heart failure (DHF). In SHF, characterized by high end-diastolic volume (EDV), the left ventricle (LV) cannot eject a normal stroke volume (SV); in DHF, with normal or low EDV, the LV cannot accept a normal venous return. These syndromes are now generally de...
Source: European Heart Journal - February 1, 2016 Category: Cardiology Authors: Katz, A. M., Rolett, E. L. Tags: Clinical update Source Type: research

Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system
Conclusions Transcatheter tricuspid valve repair by use of interventional edge-to-edge repair with the MitraClip system was feasible, and safe in three consecutive patients. Reduction of tricuspid insufficiency associates with relief of clinical symptoms for right heart failure. This strategy seems a promising treatment option for patients at prohibitive surgical risk.
Source: European Heart Journal - March 7, 2016 Category: Cardiology Authors: Hammerstingl, C., Schueler, R., Malasa, M., Werner, N., Nickenig, G. Tags: EHJ BRIEF COMMUNICATION Source Type: research

Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure
Left ventricular ejection fraction (LVEF) has been the central parameter used for diagnosis and management in patients with heart failure. A good predictor of adverse outcomes in heart failure when below ~45%, LVEF is less useful as a marker of risk as it approaches normal. As a measure of cardiac function, ejection fraction has several important limitations. Calculated as the stroke volume divided by end-diastolic volume, the estimation of ejection fraction is generally based on geometric assumptions that allow for assessment of volumes based on linear or two-dimensional measurements. Left ventricular ejection fraction is...
Source: European Heart Journal - May 31, 2016 Category: Cardiology Authors: Cikes, M., Solomon, S. D. Tags: Clinical update Source Type: research

Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention
Conclusion Hypothyroidism is associated with a higher incidence of MACCE compared with euthyroidism in patients undergoing PCI. Maintaining adequate control on TRT is beneficial in preventing MACCE.
Source: European Heart Journal - July 10, 2016 Category: Cardiology Authors: Zhang, M., Sara, J. D. S., Matsuzawa, Y., Gharib, H., Bell, M. R., Gulati, R., Lerman, L. O., Lerman, A. Tags: Coronary artery disease Source Type: research